Cantor Fitzgerald initiated coverage of Incyte with a Neutral rating. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on INCY: Incyte gets payment from CMS Skinhealth for povorcitinib commercialization Incyte, CMS enter collaboration, license agreement for povorcitinib in China Incyte participates in a conference call with JPMorgan Incyte price target lowered to $67 from $69 at BofA Incyte to hold a conference call